CRIM2 Antibody | 6963

CRIM2 Antibody | 6963 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: CRIM2 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human CRIM2.
The immunogen is located within amino acids 1320 - 1370 of CRIM2.

Research Area: Stem Cell

Tested Application: E, WB

Application: CRIM2 antibody can be used for detection of CRIM2 by Western blot at 1 - 2 μg/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.

Specificiy: At least two isoforms of CRIM2 are known to exist; this antibody will only detect the larger isoform. CRIM2 antibody is predicted to not cross-react with CRIM1.

Positive Control 1: Cat. No. 1205 - Jurkat Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: CRIM2 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: CRIM2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: CRIM2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: CRIM2 Antibody: KCP1, CRIM2, NET67, KCP1, Cysteine-rich BMP regulator 2, CRIM-2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CRIM2 Antibody: CRIM2, also known as Kielin/chordin-like protein (KCP) , is a novel enhancer of BMP signaling. It binds to BMP7, a morphogen that is important for kidney development and part of the kidney's physiological response to repair of acute kidney injury, enhancing its binding to its receptor. Because of this, CRIM2 has been suggested as a potential antifibrotic therapy in acute and chronic kidney injury. CRIM2 can also interact directly with either activin or TGF-β1, suppressing activin- and TGF-β1-dependent transcription.